Literature DB >> 16876519

A Glaucoma Case-control Study of the WDR36 Gene D658G sequence variant.

Alex W Hewitt1, David P Dimasi, David A Mackey, Jamie E Craig.   

Abstract

PURPOSE: To investigate in Australian patients with glaucoma and normal controls the prevalence and associated phenotype of the WDR36 D658G mutation, which has previously been suggested to be a disease-causing mutation in pedigrees with primary open-angle glaucoma (POAG).
DESIGN: Case-control study.
METHODS: Two hundred forty-nine individuals with POAG and 217 age-matched control subjects were recruited through the Glaucoma Inheritance Study in Tasmania, Australia. Genomic DNA was amplified by polymerase chain reaction by intronic primers. The presence of the D658G variant was detected by BglI restriction enzyme digestion.
RESULTS: The D658G variant was identified in four POAG cases (1.6%) and four control subjects (1.8%) (chi(2) = 0.04, P = .84). No control subject with the variant had a family history of glaucoma.
CONCLUSIONS: The WDR36 D658G is a neutral variant in the Australian population. Further populations should be carefully assessed for this variant before concluding that WDR36 is a glaucoma gene.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16876519     DOI: 10.1016/j.ajo.2006.02.041

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  27 in total

1.  WDR36 and P53 gene variants and susceptibility to primary open-angle glaucoma: analysis of gene-gene interactions.

Authors:  Cristina Blanco-Marchite; Francisco Sánchez-Sánchez; María-Pilar López-Garrido; Mercedes Iñigez-de-Onzoño; Francisco López-Martínez; Enrique López-Sánchez; Lydia Alvarez; Pedro-Pablo Rodríguez-Calvo; Carmen Méndez-Hernández; Luis Fernández-Vega; Julián García-Sánchez; Miguel Coca-Prados; Julián García-Feijoo; Julio Escribano
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-31       Impact factor: 4.799

Review 2.  When ribosomes go bad: diseases of ribosome biogenesis.

Authors:  Emily F Freed; Franziska Bleichert; Laura M Dutca; Susan J Baserga
Journal:  Mol Biosyst       Date:  2010-01-11

Review 3.  Glaucoma genetics.

Authors:  Pratap Challa
Journal:  Int Ophthalmol Clin       Date:  2008

Review 4.  A molecular mechanism for glaucoma: endoplasmic reticulum stress and the unfolded protein response.

Authors:  Robert R H Anholt; Mary Anna Carbone
Journal:  Trends Mol Med       Date:  2013-07-19       Impact factor: 11.951

Review 5.  Primary open-angle glaucoma genes.

Authors:  J H Fingert
Journal:  Eye (Lond)       Date:  2011-05       Impact factor: 3.775

6.  Copy number variations on chromosome 12q14 in patients with normal tension glaucoma.

Authors:  John H Fingert; Alan L Robin; Jennifer L Stone; Ben R Roos; Lea K Davis; Todd E Scheetz; Steve R Bennett; Thomas H Wassink; Young H Kwon; Wallace L M Alward; Robert F Mullins; Val C Sheffield; Edwin M Stone
Journal:  Hum Mol Genet       Date:  2011-03-29       Impact factor: 6.150

7.  TBK1 and flanking genes in human retina.

Authors:  John H Fingert; Benjamin W Darbro; Qining Qian; Richard Van Rheeden; Kathy Miller; Megan Riker; Frances Solivan-Timpe; Ben R Roos; Alan L Robin; Robert F Mullins
Journal:  Ophthalmic Genet       Date:  2013-02-20       Impact factor: 1.803

8.  Identification of proteins that interact with TANK binding kinase 1 and testing for mutations associated with glaucoma.

Authors:  Seongjin Seo; Frances Solivan-Timpe; Ben R Roos; Alan L Robin; Edwin M Stone; Young H Kwon; Wallace L M Alward; John H Fingert
Journal:  Curr Eye Res       Date:  2013-01-03       Impact factor: 2.424

Review 9.  Molecular complexity of primary open angle glaucoma: current concepts.

Authors:  Kunal Ray; Suddhasil Mookherjee
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

10.  Fine mapping of new glaucoma locus GLC1M and exclusion of neuregulin 2 as the causative gene.

Authors:  Bao Jian Fan; Wendy Charles Ko; Dan Yi Wang; Oscar Canlas; Robert Ritch; Dennis S C Lam; Chi Pui Pang
Journal:  Mol Vis       Date:  2007-05-23       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.